RT Journal Article T1 Infective endocarditis in hypertrophic cardiomyopathy: A multicenter, prospective, cohort study. A1 Dominguez, Fernando A1 Ramos, Antonio A1 Bouza, Emilio A1 Muñoz, Patricia A1 Valerio, Maricela C A1 Fariñas, M Carmen A1 de Berrazueta, José Ramón A1 Zarauza, Jesús A1 Pericás Pulido, Juan Manuel A1 Paré, Juan Carlos A1 de Alarcón, Arístides A1 Sousa, Dolores A1 Rodriguez Bailón, Isabel A1 Montejo-Baranda, Miguel A1 Noureddine, Mariam A1 García Vázquez, Elisa A1 Garcia-Pavia, Pablo AB Infective endocarditis (IE) complicating hypertrophic cardiomyopathy (HCM) is a poorly known entity. Although current guidelines do not recommend IE antibiotic prophylaxis (IEAP) in HCM, controversy remains.This study sought to describe the clinical course of a large series of IE HCM and to compare IE in HCM patients with IE patients with and without an indication for IEAP.Data from the GAMES IE registry involving 27 Spanish hospitals were analyzed. From January 2008 to December 2013, 2000 consecutive IE patients were prospectively included in the registry. Eleven IE HCM additional cases from before 2008 were also studied. Clinical, microbiological, and echocardiographic characteristics were analyzed in IE HCM patients (n = 34) and in IE HCM reported in literature (n = 84). Patients with nondevice IE (n = 1807) were classified into 3 groups: group 1, HCM with native-valve IE (n = 26); group 2, patients with IEAP indication (n = 696); group 3, patients with no IEAP indication (n = 1085). IE episode and 1-year follow-up data were gathered.One-year mortality in IE HCM was 42% in our study and 22% in the literature. IE was more frequent, although not exclusive, in obstructive HCM (59% and 74%, respectively). Group 1 exhibited more IE predisposing factors than groups 2 and 3 (62% vs 40% vs 50%, P  YR 2016 FD 2016 LK http://hdl.handle.net/10668/10231 UL http://hdl.handle.net/10668/10231 LA en DS RISalud RD Jul 7, 2025